CDXC Nasdaq· ChromaDex Corporation
FundamentalsNews digest Peer analysis
CDXC Nasdaq· ChromaDex Corporation
Earnings report Q3 2023

ChromaDex Corporation Reports Strong Revenue Growth in Latest Quarter

Segments of revenue

In the latest quarter, ChromaDex Corporation reported total revenue of $25.6 million, representing a significant increase of 35% compared to the same quarter last year. The company's revenue growth was primarily driven by strong performance across its key segments.


ChromaDex Corporation demonstrated several strengths in its latest quarter. The company experienced robust revenue growth, which can be attributed to the successful execution of its business strategies and the increasing demand for its products. Management highlighted the strong sales performance of its flagship product, Tru Niagen®, a patented form of nicotinamide riboside, which contributed significantly to the overall revenue growth. Additionally, the company's expansion into new markets and partnerships with key retailers have further bolstered its revenue generation capabilities.


Despite the positive revenue growth, ChromaDex Corporation faced certain challenges in its latest quarter. The company experienced increased operating expenses, primarily driven by investments in research and development, marketing, and sales initiatives. These expenses impacted the company's profitability and resulted in a net loss for the quarter. Furthermore, the company faced competitive pressures in the market, which may pose challenges to its future revenue growth.


It is worth mentioning that ChromaDex Corporation continued to strengthen its intellectual property portfolio during the quarter. The company secured additional patents for its proprietary technologies, providing a competitive advantage and further protecting its innovative products. This intellectual property expansion positions the company well for future growth and differentiation in the market.


ChromaDex Corporation delivered a strong performance in its latest quarter, with a notable increase in revenue. The company's revenue growth was driven by the successful sales of its flagship product, Tru Niagen®, and its expansion into new markets. However, increased operating expenses and competitive pressures remain challenges for the company. Overall, ChromaDex Corporation's strong revenue growth and focus on intellectual property development position it well for future success in the market.

Source documents

Form 10-Q  filed on Nov 08, 2023
75 pages scanned

Reference data

Company financials Q3 revenue 21.2M
Analyst estimates Q3 EPS missed by -100.00%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.